We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · July 07, 2020

Neutrophil-to-Lymphocyte Ratio Predicts Outcomes in mRCC and mNSCLC Patients Treated With Nivolumab

Cancer Immunology, Immunotherapy: CII


Additional Info

Cancer Immunology, Immunotherapy: CII
Variation in Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Outcomes in Metastatic Renal Cell Carcinoma (mRCC) and Non-Small Cell Lung Cancer (mNSCLC) Patients Treated With Nivolumab
Cancer Immunol. Immunother. 2020 Jun 19;[EPub Ahead of Print], A Simonaggio, R Elaidi, L Fournier, E Fabre, V Ferrari, D Borchiellini, J Thouvenin, P Barthelemy, C Thibault, E Tartour, S Oudard, YA Vano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading